Licraside as novel potent FXR agonist for relieving cholestasis: structure-based drug discovery and biological evaluation studies

• Egile Nagusiak: Lili Xi (Egilea), Axi Shi (Egilea), Tiantian Shen (Egilea), Guoxu Wang (Egilea), Yuhui Wei (Egilea), Jingjing Guo (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2023-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Cholestasis is a common clinical disease caused by a disorder in bile acids (BAs) homeostasis, which promotes its development. The Farnesoid X receptor (FXR) plays a critical role in regulating BAs homeostasis, making it an essential target for cholestasis treatment. Although several active FXR agon...